Your browser doesn't support javascript.
loading
Long-term outcome of alcohol withdrawal seizures.
Sansone, Giulio; Megevand, Pierre; Vulliémoz, Serge; Corbetta, Maurizio; Picard, Fabienne; Seeck, Margitta.
Affiliation
  • Sansone G; Department of Clinical Neurosciences, University Hospital of Geneva & Faculty of Medicine, Geneva, Switzerland.
  • Megevand P; Department of Neuroscience, University of Padova, Padova, Italy.
  • Vulliémoz S; Department of Clinical Neurosciences, University Hospital of Geneva & Faculty of Medicine, Geneva, Switzerland.
  • Corbetta M; Department of Clinical Neurosciences, University Hospital of Geneva & Faculty of Medicine, Geneva, Switzerland.
  • Picard F; Department of Neuroscience, University of Padova, Padova, Italy.
  • Seeck M; Padova Neuroscience Center (PNC), University of Padova, Padova, Italy.
Eur J Neurol ; 31(1): e16075, 2024 01.
Article de En | MEDLINE | ID: mdl-37823698
ABSTRACT
BACKGROUND AND

PURPOSE:

Alcohol withdrawal seizures (AWS) are a well-known complication of chronic alcohol abuse, but there is currently little knowledge of their long-term relapse rate and prognosis. The aims of this study were to identify risk factors for AWS recurrence and to study the overall outcome of patients after AWS.

METHODS:

In this retrospective single-center study, we included patients who were admitted to the Emergency Department after an AWS between January 1, 2013 and August 10, 2021 and for whom an electroencephalogram (EEG) was requested. AWS relapses up until April 29, 2022 were researched. We compared history, treatment with benzodiazepines or antiseizure medications (ASMs), laboratory, EEG and computed tomography findings between patients with AWS relapse (r-AWS) and patients with no AWS relapse (nr-AWS).

RESULTS:

A total of 199 patients were enrolled (mean age 53 ± 12 years; 78.9% men). AWS relapses occurred in 11% of patients, after a median time of 470.5 days. Brain computed tomography (n = 182) showed pathological findings in 35.7%. Risk factors for relapses were history of previous AWS (p = 0.013), skull fractures (p = 0.004) at the index AWS, and possibly epileptiform EEG abnormalities (p = 0.07). Benzodiazepines or other ASMs, taken before or after the index event, did not differ between the r-AWS and the nr-AWS group. The mortality rate was 2.9%/year of follow-up, which was 13 times higher compared to the general population. Risk factors for death were history of AWS (p < 0.001) and encephalopathic EEG (p = 0.043).

CONCLUSIONS:

Delayed AWS relapses occur in 11% of patients and are associated with risk factors (previous AWS >24 h apart, skull fractures, and pathological EEG findings) that also increase the epilepsy risk, that is, predisposition for seizures, if not treated. Future prospective studies are mandatory to determine appropriate long-term diagnostic and therapeutic strategies, in order to reduce the risk of relapse and mortality associated with AWS.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Fractures du crâne / Syndrome de sevrage / Crises épileptiques du sevrage alcoolique / Alcoolisme Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Eur J Neurol Sujet du journal: NEUROLOGIA Année: 2024 Type de document: Article Pays d'affiliation: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Fractures du crâne / Syndrome de sevrage / Crises épileptiques du sevrage alcoolique / Alcoolisme Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Eur J Neurol Sujet du journal: NEUROLOGIA Année: 2024 Type de document: Article Pays d'affiliation: Suisse